Thyroid carcinomas of the follicular epithelium: Tumor markers and oncogenes;Carcinoma tiroideo del epitelio folicular: Marcadores tumorales y oncogenes

Medicina Clinica

Volumn 121, Issue 7, 2003, Pages 264-269

  Álvarez Núñez, Francisco ^a   Mora, Josefina ^a   Matías Guiu, Xavier ^a   Bagué, Silvia ^a   de Leiva Hidalgo, Alberto ^a   Lerma, Enrique ^a   Martín Campos, Jesus M ^a   Rius, Xavier ^a   Rodriguez Espinosa, José ^a   Vilar, Mónica ^a   Wagner, Ana ^a   Ybarra, Juan ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Differentiated thyroid carcinomas; Gen sequence; Polymerase chain reaction; Reverse transcription; Tumor markers

Indexed keywords

BETA CATENIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTAGLANDIN SYNTHASE; TELOMERASE; THYROGLOBULIN; THYROTROPIN RECEPTOR; TRANSCRIPTION FACTOR; TUMOR MARKER;

CANCER CELL; CANCER DIAGNOSIS; CARCINOGENESIS; CELL GROWTH; CHROMOSOME REARRANGEMENT; DIAGNOSTIC ACCURACY; GENE CONTROL; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GROWTH INHIBITION; HOSPITAL COST; HUMAN; MOLECULAR BIOLOGY; ONCOGENE; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REGULATORY MECHANISM; REVERSE TRANSCRIPTION; REVIEW; SOMATIC MUTATION; THYROID FOLLICLE CELL; THYROID FOLLICULAR CARCINOMA; THYROID TUMOR; TISSUE GROWTH; TUMOR SUPPRESSOR GENE;

EID: 0141669243     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13050439     Document Type: Review

References (63)

1. Gimm O. Thyroid cancer [review]. Cancer Lett 2001;163:143-56.
2. Soria JC, Lee HY, Lee JI, Wang L, Issa JP, Kemp BL, et al. Lack of PTEN expression in Non-Small cell lung cancer could be related to promoter methylation. Clin Cancer Res 2002;8:1178-84.
3. Gimm O, Chi H, Dahia PL, Perren A, Hinzo R, Komminoth P, et al. Somatic mutation and germline variants of MINPP1, a phosphatase gene located in proximity to PTEN on 10q23.3, in follicular thyroid carcinomas. J Clin Endocrinol Metab 2001;86: 1801-5.
4. Podsypanina K, Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM, et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA 1999;96:1563-8.
5. Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997;16: 64-7.
6. Nelen MR, Van Staveren WCG, Peeters EAJ, Hassel MB, Gorlin RJ, Hamm H, et al. Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum Mol Genet 1997;6:1383-7.
7. Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, Wang SI, et al. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 1997;57:3935-40.
8. Bussaglia E, Del Río E, Matias-Guiu X, Prat J. PTEN mutations in endometrial carcinomas: a molecular and clinicopathologic análisis of 38 cases. Hum Pathol 2000;31:312-7.
9. Dahia PL, Marsh DB, Zheng Z, Zedenius J, Komminoth P, Frisk T, et al. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res 1997;57:4710-3.
10. Halachmi N, Halachmi S, Euron E, Cairns P, Okami K, Saji M, et al. Somatic mutations of the PTEN tumor suppressor gene in sporadic follicular thyroid tumors. Genes Chromosomes Cancer 1998;23:239-43.
11. Gimm O, Perren A, Weng LP, Marsh DJ, Yeh JJ, Ziebold U. Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and beningn and malignant epithelial thyroid tumors. Am J Pathol 2000;156:1693-700.
12. Zhou XP, Gimm O, Hampel H, Niemann T, Walker MJ, Eng C. Epigenetic PTEN silencing in malignant melanomas without PTEN mutation. Am J Pathol 2000;157:1123-8.
13. Strathdee G, Brown R. Aberrant DNA methylation in cancer: potential clinical interventions [review]. Experts Reviews in Molecular Medicine, March 2002. Disponible en: www-ermm.cbcu.cam.ac.uk
14. Heard E, Clerc P, Avner P. X-chromosome inactivation in mammals [review]. Annu Rev Genet 1997;31:571-610.
15. Li E, Bestor TH, Jaenisch R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 1992;69:915-26.
16. Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999;99:451-4.
17. Antequera F, Boyes J, Bird A. High levels of the novo methylation and altered chromatin structure at CpG islands in cell lines. Cell 1990;62:503-14.
18. Tyler JK, Kadonaga JT. The «dark side» of chromatin remodelling: repressive effects on transcription [review]. Cell 1999;99:443-6.
19. Salvesen HB, MacDonald N, Ryan A, Jacobs IJ, Lynch ED, Aíslen LA, et al. PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int J Cancer 2001;91:22-6.
20. Zysman MA, Chapman WB, Bapat B. Considerations when analyzing the methylation status of PTEN tumor suppressor gene. Am J Pathol 2002; 160:795-800.
21. Dahia PL, FitzGerald MG, Zhang X, Marsh DJ, Zheng Z, Pietsch T, et al. A highly conserved processed PTEN pseudogene is located on chromosome band 9p21. Oncogene 1998; 16:2403-6.
22. Herman JG, Graff JR, Myöhönen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996;93:9821-6.
23. Holt SE, Shay JW. Role of telomerase in cellular proliferation and cancer [review]. J Cell Physiol 1999;180:10-8.
24. Reddel RR. The role of senescence and immortalization in carcinogenesis [review]. Carcinogenesis 2000;21:477-84.
25. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defined genetic elements. Nature 1999;400:464-8.
26. Keith WN, Bilsland A, Evans TRJ, Glasspool RM. Telomerase-directed molecular therapeutics. Expert Reviews in Molecular Medicine, April 2002. Disponible en: www-ermm.cbcu.cam.ac.uk
27. Umbricht CB, Saji M, Westra WH, Udelsman R, Zeiger MA, Sukumar S. Telomerase activity: a marker to distinguish follicular thyroid adenoma from carcinoma. Cancer Res 1997;57:2144-7.
28. Saji M, Westra W, Chen H, Umbricht CB, Tuttle RM, Box MF, et al. Telomerase activity in differential diagnosis of papillary carcinoma of the thyroid. Surgery 1997;122:1137-40.
29. Cheng AJ, Lin JD, Chang T, Wang TCV. Telomerase activity in benign and malignant human thyroid tissues. Br J Cancer 1998;77:2177-80.
30. Aogi K, Kitahara K, Buley I, Backdahl M, Tahara H, Sugino T, et al. Telomerase activity in lesions of the thyroid: application to diagnosis of clinical samples including fine-needle aspirates. Clin Cancer Res 1998;4:1965-70.
31. Grieco M, Santoro M, Berlingeri MT, Melillo RM, Donghi M, Bongarzone I, et al. PTC is a novel rearranged form of the ret proto-oncogene an is frequently detected in vivo in human thyroid papillary carcinomas. Cell 1990;60:557-63.
32. Roque L, Nunes VM, Ribero C, Martins C, Soares J. Karyotypic characterization of papillary thyroid carcinomas. Cancer 2001;92:2529-38.
33. Oriola J, Halperin I, Mallofré C, Muntané J, Angel M, Rivera-Fillat F. Screening of selected genomic areas potentially involved in thyroid neoplasms. Eur J Cancer 2001;37:2470-4.
34. Bongarzone I, Monzini N, Borrello MG, Carcano C, Ferraresi G, Arighi E, et al. Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit RI alpha of cyclic AMP-dependent protein kinase A. Mol Cell Biol 1993;13:358-66.
35. Santoro M, Dathan NA, Berlingeri MT, Bongarzone I, Paulin C, Grieco M, et al. Molecular characterization of RET/PTC3: a novel rearranged version of the RET proto-oncogene in a human thyroid papillary carcinoma. Oncogene 1994;9:509-16.
36. Fugazzola L, Pierotti M, Vigano E, Pacini F, Vorontsova TV, Bongarzone I. Molecular and biochemical analysis of RET/PTC4, a novel oncogenic rearrangement between RET and ELE1 genes, in a post-Chernobyl papillary thyroid cancer. Oncogene 1996;13:1093-7.
37. Klugbauer S, Demidchik EP, Lengfelder E, Rabes HM. Detection of a novel type of RET rearrangement (PTC5) in thyroid carcinomas after Chernobyl and analysis of the RET-fused gene RFG5. Cancer Res 1998;58:198-203.
38. Klugbauer S, Rabes HM. The transcription coactivator HTIF1 and a related protein are fused to the RET receptor tyrosine kinase in childhood papillary carcinomas. Oncogene 1999;18:4388-93.
39. Salassidis K, Bruch J, Zitzelberger H, Lengfelder E, Kellerer AM, Bauchinger M. Translocation t(10;14)(q11.2;q22.1) fusing the kinectin to the RET gene creates a novel rearranged form (PTC8) of the RET protooncogene in radiation-induced childhood papillary thyroid carcinoma. Cancer Res 2000;60:2786-9.
40. Santoro M, Thomas GA, Vecchio G, Williams GH, Fusco A, Chiappetta G, et al. Gene rearrangement and Chernobyl related thyroid cancers. Br J Cancer 2000;82:315-22.
41. García-Rostan G, Tallini G, Herrero A, D'Aquila TG, Carcangiu ML, Rimm DL. Frequent mutation and nuclear localization of beta-catenin in anaplastia thyroid carcinoma. Cancer Res 1999;59:1811-5.
42. Rocha AS, Soares P, Seruca R, Máximo V, Matias-Guiu X, Cameselle-Teijeiro J, et al. Abnormalities of the E-cadherin/catenin adhesión complex in classical papillary thyroid carcinoma and its diffuse sclerosing variant. J Pathol 2001;194:358-66.
43. Orford K, Crockett C, Jensen JP, Weissman AM, Byers SW. Serine phosphorylation-regulated ubiquitination and degradation of β-catenin. J Biol Chem 1997;272:24735-8.
44. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. β-catenin is a target for the ubiquitin-proteasome pathway. EMBO J 1997;16:3797-804.
45. Behrens J, Von Kries JP, Kuhl M, Bruhn L, Wedlich D, Grosschedl R, et al. Functional interaction of β-catenin with the transcription factor LEF-1. Nature 1996;382:638-42.
46. Lazzereschi D, Sambuco L, Carnovale Scalzo C, Ranieri A, Mincione G, Nardi F, et al. Cyclin D1 and cyclin E expression in malignant thyroid cells and in human thyroid carcinomas. Int J Cancer 1998;76:806-11.
47. Ishigaki K, Namba H, Nakashima M, Nakayama T, Mitsutake N, Hayashi T, et al. Aberrant localization of β-catenina correlates with overexpression of its target gene in human papillary thyroid cancer. J Clin Endocrinol Metab 2002;87:3433-40.
48. Cerrato A, Fulciniti F, Avallone A, Benicasa G, Palombini L, Grieco M. Beta- and gamma-catenin expresión in thyroid carcinomas. J Pathol 1998;185:267-72.
49. Huang SH, Wu JC, Chang KJ, Liaw KY, Wang SM. Expression of the cadherin-catenin complex in well differentiated human thyroid neoplastic tissue. Thyroid 1999;9:1095-103.
50. García-Rostan G, Camp RL, Herrero A, Carcangiu ML, Rimm DL, Tallini G. β-catenin clysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and ctnnb1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am J Pathol 2001; 158:987-96.
51. Rabbitts TH. Chromosomal translocations in human cancer [review]. Nature 1994;372:143-9.
52. Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Spiegelman BM, et al. PAX8-PPARγ1 fusion oncogen in human thyroid carcinoma. Science 2000;289:1357-60.
53. Poleev A, Wendler F, Fickenscher H, Zannini MS, Yaginuma K, Abbott C, et al. Distinct functional properties of three human paired-box-protein, PAX8 isoforms generated by alternative splicing in thyroid, kidney and Wilm's tumors. Eur J Biochem 1995;228:899-911.
54. Demetri GD, Fletcher CD, Mueller E, Sarraf P, Naujoks R, Campbell N, et al. Introduction of solid tumor differentiation by the peroxisome proliferator-activated receptor-γ ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci USA 1999;96:3951-6.
55. Suh N, Wang Y, Williams CR, Risingsong R, Gilmer T, Willson TM, et al. A new ligand for the peroxisome-activated receptor-γ (PPAR-γ), GW7845 inhibits rat mammary carcinogenesis. Cancer Res 1999;59:5671-3.
56. Marques AR, Espadinha C, Catarino AL, Moniz S, Pereira T, Sobrinho LG, et al. Expression of PAX8-PPARγ1 rearrangements in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 2002;87: 3947-52.
57. Specht MC, Tucker ON, Hocever M, González D, Teng L, Fahey TJ III. Cyclooxygenase-2 expression in thyroid nodules. J Clin Endocrinol Metab 2002;87:358-63.
58. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 1998;58:362-6.
59. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, Dubois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-16.
60. Huang M, Stolina M, Sharma S, Mao JT, Zhu L, Miller PW, et al. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res 1998;58:1208-16.
61. Solomon BL, Wartofsky L, Burman KD. Current trends in the management of well differentiated papillary thyroid carcinoma. J Clin Endocrinol Metab 1996;81:333-9.
62. Spencer CA, Wang CC. Thyroglobulin measurement: techniques, clinical benefits, and pitfalls [review]. Endocrinol Metab Clin North Am 1995; 24:841-63.
63. Gupta MK, Taguba L, Arciaga R, Siperstein A, Faiman C, Mehta A, et al. Detection of circulating thyroid cancer cells by reverse transcription-PCR for thyroid-stimulating hormone receptor and thyroglobulin: the importance of primer selection. Clin Chem 2002;48:1862-5.